Sara Bonstein
CIK: 0001604019
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (52 total)
- Jun 11, 2026XLO
Xilio Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
5K shares- - Jun 3, 2026INSM
INSMED Inc
Sale(S)Direct2.4K shares at avg. $102.27$246K - May 13, 2026INSM
INSMED Inc
Sale(S)Direct8.3K shares at avg. $116.18$961K - Feb 3, 2026INSM
INSMED Inc
Sale(S)Direct748 shares at avg. $156.34$117K - Jan 8, 2026INSM
INSMED Inc
Sale(S)Direct1.4K shares at avg. $174.17$252K - Jan 7, 2026INSM
INSMED Inc
Sale(S)Direct1.7K shares at avg. $175.07$294K - Jan 6, 2026INSM
INSMED Inc
Sale(S)Direct1.5K shares at avg. $173.33$263K - Jan 2, 2026INSM
INSMED Inc
Award(A)Direct6K shares- - Jan 2, 2026INSM
INSMED Inc
Award(A)Direct5.6K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
Disposition(D)DirectStock Option (Right to Buy)
19.8K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
Disposition(D)DirectStock Option (Right to Buy)
16.3K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
Disposition(D)DirectStock Option (Right to Buy)
30K shares- - Jul 21, 2025INSM
INSMED Inc
Exercise(M)Direct15.9K shares at avg. $29.13$463K - Jul 21, 2025INSM
INSMED Inc
Exercise(M)Direct3.4K shares at avg. $26.46$91K - Jul 21, 2025INSM
INSMED Inc
Sale(S)Direct26.3K shares at avg. $103.03$2.7M - Jul 21, 2025INSM
INSMED Inc
Sale(S)Direct32.1K shares at avg. $102.38$3.3M - Jul 21, 2025INSM
INSMED Inc
Exercise(M)Direct11.5K shares at avg. $28.88$331K - Jul 21, 2025INSM
INSMED Inc
Exercise(M)Direct17.1K shares at avg. $34.03$582K - Jul 7, 2025INSM
INSMED Inc
Sale(S)Direct35.6K shares at avg. $95.66$3.4M - Jul 7, 2025INSM
INSMED Inc
Exercise(M)Direct6.2K shares at avg. $19.74$123K - Jul 7, 2025INSM
INSMED Inc
Sale(S)Direct22.2K shares at avg. $96.19$2.1M - Jul 7, 2025INSM
INSMED Inc
Exercise(M)Direct23.6K shares at avg. $26.43$623K - Jul 7, 2025INSM
INSMED Inc
Exercise(M)Direct4.4K shares at avg. $24.70$108K - Jul 7, 2025INSM
INSMED Inc
Exercise(M)Direct13.7K shares at avg. $26.46$363K - Jun 23, 2025INSM
INSMED Inc
Sale(S)Direct49.1K shares at avg. $101.71$5.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  XLO Xilio Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 5,000 | - | - | Direct |
| Jun 3, 2026 |  INSM INSMED Inc | Sale(S) | 2,404 | $102.27 | $245,857 | Direct |
| May 13, 2026 | INSM INSMED Inc | Sale(S) | 8,272 | $116.18 | $961,041 | Direct |
| Feb 3, 2026 | INSM INSMED Inc | Sale(S) | 748 | $156.34 | $116,942 | Direct |
| Jan 8, 2026 | INSM INSMED Inc | Sale(S) | 1,447 | $174.17 | $252,024 | Direct |
| Jan 7, 2026 | INSM INSMED Inc | Sale(S) | 1,678 | $175.07 | $293,767 | Direct |
| Jan 6, 2026 | INSM INSMED Inc | Sale(S) | 1,517 | $173.33 | $262,942 | Direct |
| Jan 2, 2026 | INSM INSMED Inc | Award(A) | 5,998 | - | $0 | Direct |
| Jan 2, 2026 | INSM INSMED Inc | Award(A) | 5,645 | - | $0 | Direct |
| Oct 7, 2025 |  SCPH scPharmaceuticals Inc. | Disposition(D) Stock Option (Right to Buy) | 19,750 | - | - | Direct |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | Disposition(D) Stock Option (Right to Buy) | 16,300 | - | - | Direct |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | Disposition(D) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Exercise(M) | 15,890 | $29.13 | $462,876 | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Exercise(M) | 3,443 | $26.46 | $91,102 | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Sale(S) | 26,310 | $103.03 | $2,710,719 | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Sale(S) | 32,090 | $102.38 | $3,285,374 | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Exercise(M) | 11,455 | $28.88 | $330,820 | Direct |
| Jul 21, 2025 | INSM INSMED Inc | Exercise(M) | 17,100 | $34.03 | $581,913 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Sale(S) | 35,583 | $95.66 | $3,403,870 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Exercise(M) | 6,244 | $19.74 | $123,257 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Sale(S) | 22,181 | $96.19 | $2,133,590 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Exercise(M) | 23,565 | $26.43 | $622,823 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Exercise(M) | 4,362 | $24.70 | $107,741 | Direct |
| Jul 7, 2025 | INSM INSMED Inc | Exercise(M) | 13,717 | $26.46 | $362,952 | Direct |
| Jun 23, 2025 | INSM INSMED Inc | Sale(S) | 49,104 | $101.71 | $4,994,368 | Direct |
1-25 of 52 transactions
About Bonstein Sara
Bonstein Sara (SEC CIK 0001604019) files insider reports with the SEC as Director of Latigo Biotherapeutics, Inc. (LTGO), Director of Xilio Therapeutics, Inc. (XLO) and Chief Financial Officer of INSMED Inc (INSM). Signal8 also holds filings tied to 1 other company.
Signal8 holds 21 ownership filings by Bonstein Sara (1 Form 3, 20 Form 4), filed between Jan 10, 2025 and Aug 6, 2026. Those filings report 52 transactions, from Jan 7, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bonstein Sara's filings is in BRIDGEWATER, NJ.
Recent filings by Bonstein Sara
- Jun 11, 2026: Grant or award of XLO derivative securities (Form 4, code A).
- Jun 3, 2026: Open-market sale of INSM shares (Form 4, code S).
- May 13, 2026: Open-market sale of INSM shares (Form 4, code S).
- Feb 3, 2026: Open-market sale of INSM shares (Form 4, code S).
- Jan 8, 2026: Open-market sale of INSM shares (Form 4, code S).
Other insiders filing for Latigo Biotherapeutics, Inc. (LTGO)
- 5AM Ventures VI, L.P., 10% Owner
- Sanofi, 10% Owner
- Westlake BioPartners Fund I, L.P., 10% Owner
- Foresite Capital Management V, LLC, 10% Owner
- SMITH TODD N, Director
- Tananbaum James B., Director